ESSENCA
DEAD

Serial Number

88711676

Owner

Essenlix Corporation

Attorney

Julian D. Gonzalez

Filing Date

Dec 2, 2019

Add to watchlist:

No watchlists yet
View on USPTO

ESSENCA Trademark

Serial Number: 88711676

ESSENCA is a trademark filed by Essenlix Corporation on December 2, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Essenlix Corporation (147 trademarks)

7 Foulet Dr
Princeton, CA 08540

Entity Type: 03

Trademark Details

Filing Date

December 2, 2019

Registration Date

Not Registered

Published for Opposition

September 15, 2020

Goods & Services

Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents and assays for testing cells, proteins, small molecules, nucleotides, and nucleic acids; Medical diagnostic reagents; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Diagnostic biomarker reagents for medical purposes; Biological and chemical testing kits for personal wellness in the nature of diagnostic test kits consisting primarily of medical diagnostic reagents and assays for testing of bodily fluids and substances examined in bodily fluids, namely, cells, proteins, small molecules, nucleotides, and nucleic acids for use in disease detection, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Medicines for medical and veterinary purposes for cancers, blood abnormalities, immune disease, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Medical diagnostic reagents and assays for testing bodily fluids for the prevention of disease in the nature of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases; Medical diagnostic reagents and assays for testing bodily fluids for monitoring and testing illnesses and disorders in the nature of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases

Assays for research purposes; Biological and chemical reagents used for non-medical research and laboratory purposes, namely, in vitro and in vivo scientific use, the testing of bodily fluids, and the detecting and analyzing of cells, proteins, small molecules, and nucleotides; Biological and chemical test kits comprised of biological, chemical, and diagnostic reagents for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, for laboratory and research use

Medical services; Medical assistance; Medical consultations; Medical counseling; Medical information; Nutrition counseling; Healthcare services in the field of digital healthcare services, namely, the diagnosis of diseases, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Diagnostic services, namely, medical testing for diagnostic purposes; Wellness services, namely, providing wellness information in the nature of providing information in the fields of health and wellness; Medical testing services for the detection and identification of cells, proteins, small molecules, and nucleic acids in a sample in the nature of medical testing for diagnostic or treatment purposes; Health monitoring services, namely, monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Disease prevention services, namely, medical screening and testing services for preventing diseases in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Medical and healthcare services for monitoring and testing illnesses and disorders in the nature of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases

Medical diagnostic apparatus for testing cells, tissue, biomolecules, proteins, small molecules, and nucleotides; Medical devices for obtaining bodily fluid samples; Medical diagnostic instruments for the analysis of bodily fluids; Medical apparatus for diagnostic use, namely, medical apparatus for diagnostic testing of health conditions, diseases, or abnormalities, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and endocrine diseases, and other tissue-based diagnostic testing, cytology, and cell based testing; Medical apparatus, devices, and instruments for wellness testing, health condition testing, and healthcare testing, namely, point-of-care diagnostic devices, at-home diagnostic devices, and health monitoring devices that detect health conditions and diseases in the nature of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases; Medical apparatus, devices, and instruments for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, in the nature of apparatus for DNA and RNA testing for medical purposes; Medical diagnostic instruments for the analysis of body fluids in the nature of biological and chemical test kits for the detection and identification of nucleic acids, namely, DNA and RNA in a sample; Medical diagnostic apparatus for testing cells, tissue, biomolecules, proteins, small molecules, nucleic acids, and nucleotides for the prevention of disease in the nature of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 12, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 12, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 26, 2022 EXRA
SOU EXTENSION 3 GRANTED
May 25, 2022 EX3G
NOTICE OF REVIVAL - E-MAILED
May 24, 2022 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
May 23, 2022 TPEX
PETITION TO REVIVE-GRANTED
May 23, 2022 PETG
TEAS PETITION TO REVIVE RECEIVED
May 23, 2022 PROA
SOU EXTENSION 3 FILED
May 10, 2022 EXT3
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 14, 2022 EXRA
SOU EXTENSION 2 GRANTED
Jan 13, 2022 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 11, 2022 AITU
NOTICE OF REVIVAL - E-MAILED
Nov 16, 2021 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
Nov 16, 2021 TPEX
PETITION TO REVIVE-GRANTED
Nov 16, 2021 PETG
TEAS PETITION TO REVIVE RECEIVED
Nov 16, 2021 PROA
SOU EXTENSION 2 FILED
Nov 10, 2021 EXT2
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 11, 2021 EXRA
SOU EXTENSION 1 GRANTED
May 7, 2021 EX1G
SOU EXTENSION 1 FILED
May 7, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
May 7, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 10, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 15, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 15, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 13, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 11, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 11, 2020 CRFA
ASSIGNED TO LIE
Aug 9, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 22, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 22, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jan 22, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jan 22, 2020 CNRT
ASSIGNED TO EXAMINER
Jan 14, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 6, 2019 NWOS
NEW APPLICATION ENTERED
Dec 5, 2019 NWAP